InsidersTradesSigma
申报总数
公司
▲ 买入（0 笔）
▼ 卖出（16 笔）
内部人交易记录
高级管理人员已披露买入
0
已披露卖出
16
尚无足够的、已确定 T+90 期限的买入信号来衡量交易记录。
信号历史
Discover the full record of transactions filed by Hamilton James C, Chief Medical Officer. Insider active across 1 company, notably Arrowhead Pharmaceuticals, INC.. Cumulatively, 19 disclosures have been recorded. Breakdown: 0 buy · 16 sells. Total volume traded: €4.7m. History available since 1 January 2022. The latest transaction was disclosed on 23 April 2026 (Cession). Regulator: SEC (Form 4). All data is accessible without signup.
Companies and markets linked to Hamilton James C
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报19 总计
10,000 股@ US$75.000.0059% mcap15.6% 占其流量Common StockSEC:0001830755-26-000007:0
10,000 股@ US$64.1911.6% 占其流量Common StockSEC:0001830755-26-000006:0
75,000 股0Common StockSEC:0001830755-26-000004:0
4,625 股@ US$61.240.0022% mcap5.9% 占其流量Common StockSEC:0001830755-26-000002:0
20,000 股@ US$35.000.0055% mcap14.5% 占其流量Common StockSEC:0001830755-25-000011:0
15,000 股@ US$30.006.5% 占其流量Common StockSEC:0001830755-25-000009:0
15,000 股@ US$25.007.7% 占其流量Common StockSEC:0001830755-25-000007:0
611 股@ US$20.000.3% 占其流量Common StockSEC:0001830755-25-000005:0
21,758 股@ US$19.687.0% 占其流量Common StockSEC:0001628280-25-000807:1
10,971 股@ US$20.113.6% 占其流量Common StockSEC:0001628280-25-000807:2
100,000 股0Common StockSEC:0001628280-25-000807:0
6,000 股@ US$28.032.6% 占其流量Common StockSEC:0001628280-24-014735:0
4,238 股@ US$36.472.4% 占其流量Common StockSEC:0001628280-24-001576:0
3,500 股@ US$31.811.7% 占其流量Common StockSEC:0001628280-24-000748:0
3,000 股@ US$35.531.7% 占其流量Common StockSEC:0001628280-23-024351:0
7,230 股@ US$37.404.3% 占其流量Common StockSEC:0001209191-23-002479:0
1,194 股@ US$37.460.7% 占其流量Common StockSEC:0001209191-23-002110:0
9,955 股@ US$64.890.0053% mcap13.9% 占其流量Common StockSEC:0001209191-22-002284:0
55,000 股0Common StockSEC:0001209191-22-001313:0
19 条申报中的 19 条
About Hamilton James C
James C. Hamilton is the Chief Medical Officer at Arrowhead Pharmaceuticals, Inc. He oversees clinical activities and drug development strategies. His role is essential in ensuring that the products developed meet safety and efficacy standards while contributing to innovation in the pharmaceutical field.
